Xarelto vs Pomalyst
Side-by-side drug price comparison from Medicare Part D data
Verdict
Xarelto costs 98% less per claim than Pomalyst ($321.00 vs $17250.00). Xarelto has a generic alternative available. Total Medicare spending: Xarelto at $5.0B vs Pomalyst at $3.3B.
| Metric | Xarelto | Pomalyst |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $321* | $17,250 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $5.0B | $3.3B |
| Total Claims | 15,680,000 | 192,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -1.2%* | 4.7% |
| Generic Available | Yes | No |
| Condition | Blood Clots | Cancer |
| Total Beneficiaries | 1,920,000 | 18,000 |
Xarelto costs 98% less per claim than Pomalyst ($321.00 vs $17250.00). Xarelto has a generic alternative available. Total Medicare spending: Xarelto at $5.0B vs Pomalyst at $3.3B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Xarelto and Pomalyst. What follows is the interpretation — which specific axes carry the most weight for Xarelto versus Pomalyst, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual Xarelto and Pomalyst detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.